Human pluripotent stem cells in drug discovery and predictive toxicology.

Human pluripotent stem cells are a biological resource most commonly considered for their potential in cell therapy or, as it is now called, 'regenerative medicine'. However, in the near future, their most important application for human health may well be totally different, as they are more and more envisioned as opening new routes for pharmacological research. Pluripotent stem cells indeed possess the main attributes that make them theoretically fully equipped for the development of cell-based assays in the fields of drug discovery and predictive toxicology. These cells are characterized by: (i) an unlimited self-renewal capacity, which make them an inexhaustible source of cells; (ii) the potential to differentiate into any cell phenotype of the body at any stage of differentiation, with probably the notable exception, however, of the most mature forms of many lineages; and (iii) the ability to express genotypes of interest via the selection of donors, whether they be of embryonic origin, through pre-implantation genetic diagnosis, or adults, by genetic reprogramming of somatic cells, so-called iPSCs (induced pluripotent stem cells). In the present review, we provide diverse illustrations of the use of pluripotent stem cells in drug discovery and predictive toxicology, using either human embryonic stem cell lines or iPSC lines.

[1]  J. Kramer,et al.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.

[2]  S. Palecek,et al.  Scalable culture and cryopreservation of human embryonic stem cells on microcarriers , 2009, Biotechnology progress.

[3]  Wenjun Guo,et al.  Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds , 2008, Nature Biotechnology.

[4]  J. Utikal,et al.  Induced Pluripotent Stem Cells Generated Without Viral Integration , 2008, Science.

[5]  T. Hartung,et al.  First steps in establishing a developmental toxicity test method based on human embryonic stem cells. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  S. Rechitsky,et al.  Preimplantation genetic diagnosis as a source of human embryonic stem cell lines with genetic disorders , 2008 .

[7]  M. Schuldiner,et al.  Modeling for Lesch‐Nyhan Disease by Gene Targeting in Human Embryonic Stem Cells , 2004, Stem cells.

[8]  Jehyuk Lee,et al.  Generation of functional human hepatic endoderm from human induced pluripotent stem cells , 2009, Hepatology.

[9]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[10]  B. Thiers Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[11]  M. Peschanski,et al.  Human embryonic stem cells reveal recurrent genomic instability at 20q11.21 , 2008, Nature Biotechnology.

[12]  B. Jernström,et al.  Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[13]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[14]  K. Sermon,et al.  Recurrent chromosomal abnormalities in human embryonic stem cells , 2008, Nature Biotechnology.

[15]  Peter Sartipy,et al.  The application of human embryonic stem cell technologies to drug discovery. , 2007, Drug discovery today.

[16]  A. Khanna,et al.  Assessment of drug induced developmental toxicity using human embryonic stem cells , 2008, Cell biology international.

[17]  Magnus Ingelman-Sundberg,et al.  Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. , 2010, Journal of biotechnology.

[18]  H. Thomson,et al.  Bioprocessing of embryonic stem cells for drug discovery. , 2007, Trends in biotechnology.

[19]  S. Fisher,et al.  Human embryonic stem cells as a model system for studying the effects of smoke exposure on the embryo. , 2008, Reproductive toxicology.

[20]  David C Hay,et al.  Efficient Differentiation of Hepatocytes from Human Embryonic Stem Cells Exhibiting Markers Recapitulating Liver Development In Vivo , 2008, Stem cells.

[21]  S. Pickering,et al.  Preimplantation genetic diagnosis as a novel source of embryos for stem cell research. , 2003, Reproductive biomedicine online.

[22]  Marc Peschanski,et al.  Improvement of culture conditions of human embryoid bodies using a controlled perfused and dialyzed bioreactor system. , 2008, Tissue engineering. Part C, Methods.

[23]  T Seidle,et al.  The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. , 2007, Current pharmaceutical design.

[24]  Dong Wook Han,et al.  Generation of induced pluripotent stem cells using recombinant proteins. , 2009, Cell stem cell.

[25]  David A. Katz,et al.  Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy , 2008, Nature Reviews Drug Discovery.

[26]  O. Yanuka,et al.  Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. , 2007, Cell stem cell.

[27]  F. Larcher,et al.  Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical study , 2009, The Lancet.

[28]  J. Mcneish Stem cells as screening tools in drug discovery. , 2007, Current opinion in pharmacology.

[29]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[30]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[31]  M. S. Kallos,et al.  Large-scale expansion of pluripotent human embryonic stem cells in stirred-suspension bioreactors. , 2010, Tissue engineering. Part C, Methods.

[32]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[33]  D. Kehoe,et al.  Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. , 2010, Tissue engineering. Part A.

[34]  S. Bremer,et al.  Hazard assessment of methylmercury toxicity to neuronal induction in embryogenesis using human embryonic stem cells. , 2009, Toxicology.

[35]  A. Viale,et al.  Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs , 2009, Nature.

[36]  Aldert Piersma,et al.  The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: Results of the Definitive Phase and Evaluation of Prediction Models , 2002, Alternatives to laboratory animals : ATLA.

[37]  S. Flora,et al.  Monoisoamyl dimercaptosuccinic acid abrogates arsenic-induced developmental toxicity in human embryonic stem cell-derived embryoid bodies: comparison with in vivo studies. , 2009, Biochemical pharmacology.

[38]  J. Crook,et al.  Human stem cells for modeling neurological disorders: Accelerating the drug discovery pipeline , 2008, Journal of cellular biochemistry.

[39]  Susanne Bremer,et al.  Validation of the Embryonic Stem Cell Test in the International ECVAM Validation Study on Three In Vitro Embryotoxicity Tests , 2004, Alternatives to laboratory animals : ATLA.

[40]  H Nau,et al.  Species differences in pharmacokinetics and drug teratogenesis. , 1986, Environmental health perspectives.

[41]  Oliver Brüstle,et al.  Automated maintenance of embryonic stem cell cultures , 2007, Biotechnology and bioengineering.

[42]  P. Devroey,et al.  Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. , 2006, Human reproduction.

[43]  J. Mcneish Embryonic stem cells in drug discovery , 2004, Nature Reviews Drug Discovery.

[44]  C. Pouton,et al.  Pharmaceutical applications of embryonic stem cells. , 2005, Advanced drug delivery reviews.

[45]  H. Green,et al.  Marker succession during the development of keratinocytes from cultured human embryonic stem cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Eiges,et al.  PGD-derived human embryonic stem cell lines as a powerful tool for the study of human genetic disorders , 2008, Molecular and Cellular Endocrinology.

[47]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[48]  Robert Lanza,et al.  Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells , 2008, Stem cells.

[49]  Frank Stahl,et al.  Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[50]  C Mason,et al.  Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discovery , 2009, BJOG : an international journal of obstetrics and gynaecology.

[51]  H. Baharvand,et al.  Human-induced pluripotent stem cells: derivation, propagation, and freezing in serum- and feeder layer-free culture conditions. , 2010, Methods in molecular biology.